황금성게임동영상 82.rtb827.top 오리지널야마토2게임

오션파라다이스시즌7 57.rtb827.top 바로가기 바다이야기5, 백경게임하는곳주소

알라딘릴게임장무료황금성황금성어플신규릴게임

야마토3게임다운로드 87.rtb827.top 바다이야기 기계 가격

프라그마틱 슬롯 추천 21.rtb827.top 오리 지날황금성9게임

황금성 슬롯 83.rtb827.top 매장판

없습니다. 83.rtb827.top 바다이야기 시즌7

모바일야마토 3.rtb827.top 바다이야기무료

슬롯 무료체험 17.rtb827.top 황금성3게임다운로드

손오공 게임 다운 46.rtb827.top 릴게임 5만

신천지무료 39.rtb827.top 슬롯 프라 그마 틱 무료체험

바다이야기프로그램 90.rtb827.top 모바일바다이야기

꽁머니 73.rtb827.top 온라인 릴게임 사이트

게임바둑이추천 프라그마틱 무료스핀 신천지게임사이트 야마토2릴게임 바다이야기게임 슬롯 무료체험 릴게임 사이트 도메인 이벤트릴게임 우주전함 야마토 먹튀 우주 전함 야마토 2205 인터넷릴게임 황금성어플 바다이야기 먹튀사이트 릴박스 오션파라다이스7게임 황금성용가리 무료슬롯 온라인릴게임먹튀검증 바다이야기 pc용 무료게임다운로드 체리게임 야마토 바다이야기게임2018 온라인 릴게임 파칭코슬롯 먹튀 피해 복구 야마토게임하기 오션파라다이스게임하는법 바다이야기먹튀돈받기 오션슬롯 주소 오락실황금성 신천지릴게임 모바일바다이야기 강원랜드 슬롯머신 추천 바다이야기 디시 바다이야기 부활 파라 다이스 오션 릴게임5만릴게임사이다 럭키세븐 배터리게임 황금성게임다운로드 프라그마틱 무료게임 무료야마토게임 바다이야기온라인 알라딘릴게임오락실 야마토게임하기 성인놀이터 오징어릴게임 오리지널야마토2게임 바다이야기 고래 바다이야기예시 릴게임알라딘주소 바다이야기동영상 인터넷신천지 무료야마토 일본야마토게임 릴게임알라딘주소 릴게임가입머니 체리마스터 pc용 모바알바다이야기 일본빠징고 바다이야기기계 사설바둑이 먹튀 피해 복구 잘터지는 슬롯 온라인야마토주소 창공릴게임 슬롯 무료스핀 바다이야기모바일 야마토2 릴게임 무료충전바다이야기 바다이야기 apk 바다신2 영상 바다이야기무료체험 온라인 슬롯 하는 법 무료충전현금게임 오락실슬롯머신 오션파라다이스릴게임 손오공게임 오징어릴게임 모바일릴게임 황금성게임공략 법 모바일 야마토 무료 슬롯 머신 카지노 게임 빠징코 슬롯머신 야마토연타 야마토 릴게임 무료 야마토게임 알라딘릴게임장 알라딘 릴게임모바일 바다이야기고래 릴게임손오공 백경게임랜드 게임황금성 황금성게임사이트 온라인삼국지 손오공릴게임예시 게임바둑이추천 황금성배당줄 릴게임정글북 무료바다이야기 릴게임먹튀검증 바다게임사이트 릴게임뽀빠이 릴게임야마토 릴파라다이스 야마토5게임기 신야마토 바다이야기 넥슨 인터넷바다이야기게임 릴게임가입머니 무료충전 바다이야기 오션파라다이스게임다운로드 야마토2 체리마스터게임 황금성포커성 오션파라다이스 게임 알라딘설명 바다이야기 게임 다운로드 빠칭코게임 황금성포커 오락실게임 바다이야기 환전 가능 부산야마토 This article was released as Pharm Edaily Premium Content on October 26, 2025, at 12:31 PM.


[Kim Jiwan, Edaily Reporter] On October 24, Korea’s biotech market saw a surge in activity, driven by a string of positive developments in antibody-drug conjugate (ADC) and anticancer drug programs.
INTOCELL jumped sharply after resolving its patent dispute. Genome 카드사별 수수료 & Company extended gains ahead of global data disclosure for its new ADC candidate, and HLB Life Science rallied after its liver cancer trial results were published in the world-renowned medical jour 취득세 면제 대상 nal The Lancet, boosting overall investor sentiment across related stocks.
INTOCELL gains momentum after patent dispute resolved
INTOCELL continued its upward momentum after recen 지원기간 t news that its collaboration with Samsung Bioepis had been reinforced and its ADC-related patent dispute resolved.
According to KG Zeroin’s MP Doctor (formerly Market Point), INTOCELL close 한국창업보육협회 d at \48,150, up \2,850 (15.59%) from the previous session.



Tae-Kyo Park, CEO of INTOCELL (Photo = Saemi Kim, Edaily)


Sa 오션월드할인이벤트 msung Bioepis announced on the 21st that it had signed a joint research and exclusive license agreement with Chinese biotech company Frontline Biopharma to collaborate on antibody-drug conjugate (ADC) candidates. This deal effectively resolved the patent controversy surrounding INTOCELL’s core technology, “Nexatecan3.”
Frontline Biopharma, which possesses a bispecific antibody, dual payload ADC platform, is recognized as an emerging innovator in the oncology field. Under this agreement, Samsung Bioepis obtained exclusive rights to apply one of Frontline’s payload technologies, the cytotoxic component responsible for killing cancer cells, to its own development pipeline.
The issue stemmed from the fact that this payload technology was closely related to INTOCELL’s Nexatecan3, which had previously raised concerns about possible patent overlap. INTOCELL had signed a technology partnership with Samsung Bioepis in December 2023, providing its proprietary OPAS linker platform and payload technology. The two companies have since been collaborating to develop and evaluate up to five ADC candidates targeting various cancers.
However, market uncertainty lingered over potential patent infringement involving Nexatecan, and the controversy deepened when Abybel Bio terminated its technology licensing agreement with INTOCELL in July. With this new Samsung Bioepis?Frontline deal, however, concerns about INTOCELL’s patent risks appear to be resolved.
Samsung Bioepis also announced plans to jointly develop two ADC pipelines with Frontline, with “TJ108” as the first candidate. TJ108 is a dual-target ADC based on topoisomerase I and tubulin inhibitors, designed to attack both EGFR and HER3?targets commonly overexpressed in multiple solid tumors?to maximize therapeutic efficacy.
An industry official commented, “By reinforcing its partnership with Samsung Bioepis and clearing patent uncertainties, INTOCELL has regained technological credibility and is now positioned to accelerate its R&D in the ADC field.”
Genome & Company rises on anticipation of data disclosure
Genome & Company’s shares climbed on growing investor optimism as the firm prepares to unveil preclinical data for its next-generation ADC candidate, GENA-120, on the global stage.
The stock closed at \2,755, up \95 (3.57%) from the previous day.



A Genome & Company researcher conducts an experiment. (Photo provided by Genome & Company)


The company announced it will participate in the World ADC San Diego conference, held from November 3~6 (local time) in the United States, where it plans to present preclinical data for GENA-120 and discuss potential strategic collaborations with global pharma partners.
As one of the largest ADC-focused events, World ADC gathers over 1,000 global researchers, biotech firms, and investors to discuss the latest ADC technologies and commercialization strategies. Genome & Company will showcase key preclinical data demonstrating GENA-120’s anti-tumor activity and its novel target’s expression profile.
GENA-120 targets GICP-120, a new cancer biomarker discovered through Genome & Company’s AI-driven drug discovery platform, GNOCLE™. Research results show that GICP-120 is highly expressed in multiple solid tumors?including head and neck, cervical, colorectal, esophageal, and gastric cancers? but rarely found in normal tissues. The company will also present data confirming GENA-120’s strong anti-tumor efficacy in preclinical models.
Hong You-seok, Co-CEO of Genome & Company, said, “Our presentation at World ADC will showcase GENA-120’s global potential,” adding that the company “will continue to share key pipeline data at major international conferences and pursue tangible milestones such as technology licensing.”
HLB Life Science sustains gains on The Lancet publication
HLB Life Science extended its rally following the publication of clinical trial results for its liver cancer drug in The Lancet.
The stock closed at \4,485, up \615 (15.59%), after hitting an intraday high of \4,530.



The rally followed HLB’s announcement that its combination therapy of rivoceranib and camrelizumab had demonstrated over twofold improvement in disease-free survival (DFS) compared with surgery alone in patients with resectable hepatocellular carcinoma (HCC).
This marks the first clinical validation of the rivoceranib camrelizumab combination in early and intermediate-stage HCC, expanding its potential beyond previously confirmed efficacy in advanced liver cancer. The study was conducted by China’s Jiangsu Hengrui Medicine, involving 294 patients across 16 hospitals.
An HLB spokesperson said, “This outcome provides a strong foundation to extend the combination therapy strategy across the entire treatment spectrum of liver cancer.”
김지완 (2pac@edaily.co.kr)